What’s Up With Cytori CYTXJust recently joined all you irregulars and need to get over my tendency to lurk. The recent announcement that Cytori has placed further enrollment in its ATHENA and ATHENA II trials on clinical hold provided the needed stimulus for me to query the collective Gumshoe
wisdom regarding this (fortunately small) holding that I often think I’ve held too long. I would be particularly interested in your thoughts on the management—improving now finally under Hendrick??—and the financing—-my weakest suit as far as analysis goes.
Your thoughts please!
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Cytori has a moribund chart, a KSS ratio of well over 0.5, is trying to do too many trials, and no money. Its trials of stem cells for myocardial ischemia are, medically and scientifically, a fool’s errand.
This is not a quality issue. $1.65 now, next stop one buck.
Hit the ejector seat button. Why would you want to be holding onto a dog like this?